Salspera Inc. (TKVA)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	938.08M
Revenue (ttm)	n/a
Net Income	-10.73M
EPS	-0.17
Shares Out	62.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About TKVA

Salspera is focused on the development and commercialization of a new class of immunotherapeutics for the treatment of solid tumors. This new class of drugs, sometimes referred to as “live biopharmaceuticals” are genetically modified biological agents which have the capability of expressing select anti-tumoral agents within the tumor’s microenvironment. Our lead program, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and orally administered. Saltikva is being developed for the treatment of multiple oncology indica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: TKVA
• Website: https://www.salspera.com/

Financial Performance

Data Source: SEC filings Last updated: Sep 4, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error